Samsung Biologics reports third quarter 2024 financial results

Recorded Q3’24 consolidated revenue of KRW 1.2 trillion Recorded Q3’24 consolidated operating profit of KRW 338.6 billion Continued business expansion through strong competitive edge in speed and execution INCHEON, South Korea, Oct. 23, 2024 /PRNewswire/ — Samsung Biologics (KRX:…